GAMMA Investing LLC Buys 170,137 Shares of GSK plc (NYSE:GSK)

GAMMA Investing LLC increased its position in GSK plc (NYSE:GSK - Free Report) by 7,950.3% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 172,277 shares of the pharmaceutical company's stock after acquiring an additional 170,137 shares during the period. GAMMA Investing LLC's holdings in GSK were worth $66,740,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Indiana Trust & Investment Management Co lifted its stake in GSK by 200.0% in the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock valued at $25,000 after buying an additional 500 shares in the last quarter. Sierra Ocean LLC purchased a new stake in GSK in the 4th quarter valued at approximately $32,000. Parkside Financial Bank & Trust lifted its stake in GSK by 470.1% in the 4th quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company's stock valued at $34,000 after buying an additional 818 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in GSK in the 4th quarter valued at approximately $40,000. Finally, Golden State Wealth Management LLC purchased a new position in shares of GSK during the 4th quarter worth $38,000. Institutional investors and hedge funds own 15.74% of the company's stock.

GSK Stock Up 0.9%

Shares of GSK stock traded up $0.37 on Wednesday, hitting $40.83. 2,939,738 shares of the company traded hands, compared to its average volume of 4,839,095. The company has a 50-day moving average price of $37.44 and a 200 day moving average price of $36.25. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. GSK plc has a 12-month low of $31.72 and a 12-month high of $44.67. The company has a market cap of $84.24 billion, a PE ratio of 25.68, a PEG ratio of 1.12 and a beta of 0.51.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.08 by $0.05. The firm had revenue of $10.06 billion during the quarter, compared to analysts' expectations of $7.52 billion. GSK had a net margin of 8.13% and a return on equity of 48.59%. GSK's revenue for the quarter was up 2.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.43 earnings per share. Sell-side analysts predict that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Shareholders of record on Friday, May 16th will be paid a dividend of $0.4216 per share. This is a boost from GSK's previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, May 16th. This represents a $1.69 dividend on an annualized basis and a yield of 4.13%. GSK's dividend payout ratio (DPR) is currently 86.60%.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on GSK. Morgan Stanley began coverage on GSK in a research note on Wednesday, February 12th. They set an "equal weight" rating on the stock. Hsbc Global Res raised GSK to a "strong sell" rating in a research note on Monday, April 28th. Wall Street Zen lowered GSK from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Berenberg Bank reaffirmed a "hold" rating on shares of GSK in a research report on Tuesday. Finally, BNP Paribas began coverage on GSK in a research report on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 target price on the stock. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $37.38.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.